argenx SE Investor Day Presentation Deck
Multifocal Motor Neuropathy:
A Serious, Debilitating Autoimmune Disease
Need for new therapies that slow progression of disease and reduce reliance on IVlg
UNMET NEED
PREVALENCE
~13,000 patients in the U.S. -
increasing
Often underdiagnosed
Predominantly men
argenx
Median age 40 years
HALLMARK
Slowly progressive muscle
weakness due to motor neuron
degeneration
Mainly affects hands and forearms -
patients become dependent
DIAGNOSIS
Often misdiagnosed as ALS
Takes ~1.5 years for correct
diagnosis
Nerve conduction blocks
Anti-GM1 IgM antibody presence
>$0.5B IVlg sales and growing
Persson et al., Br J Dermatol. 2021; Tedbirt et al., JAMA Dermatol. 2021; Wertenteil et al., J Am Acad Dermatol. 2019; argenx market research
Steroids ineffective
First line and only approved therapy
is frequent, high doses of IVlg over
2-5 days
62View entire presentation